Intervention on toll-like receptors in pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 19, 2014, Pages 5808-5817

  Vaz, Juan ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant therapy; Intervention; Pancreatic cancer; Pathophysiological mechanism; Toll like receptor

Indexed keywords

CETUXIMAB; FOLINIC ACID; GELATINASE A; GELATINASE B; GEMCITABINE; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; KRESTIN; LIPOPOLYSACCHARIDE; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MATRIX METALLOPROTEINASE; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR MARKER;

CARCINOGENESIS; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; IMMUNE SYSTEM; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADJUVANT CHEMOTHERAPY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MICE; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84901236766     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i19.5808     Document Type: Review

References (85)

1. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465 [PMID: 1732772 DOI: 10.1056/nejm199202133260706]
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057 [PMID: 15051286 DOI: 10.1016/ S0140-6736(04)15841-8]
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
4. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009; 133: 365-374 [PMID: 19260742 DOI: 10.1043/1543-2165-133.3.365]
5. Pandol SJ, Apte MV, Wilson JS, Gukovskaya AS, Edderkaoui M. The burning question: why is smoking a risk factor for pancreatic cancer? Pancreatology 2012; 12: 344-349 [PMID: 22898636 DOI: 10.1016/j.pan.2012.06.002]
6. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 2013; 104: 9-14 [PMID: 23066889 DOI: 10.1111/cas.12043]
7. Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144: 1199-1209. e4 [PMID: 23622129 DOI: 10.1053/j.gastro.2013.02.007]
8. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008; 1: 306-316 [PMID: 18787611]
9. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007; 14: 224-232 [PMID: 17520196 DOI: 10.1007/s00534-006-1166-5]
10. Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 2013; 144: 1210-1219 [PMID: 23622130 DOI: 10.1053/j.gastro.2012.11.037]
11. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161-173 [PMID: 19582426 DOI: 10.1007/978-1-59745-280-9_10]
12. Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, Aizawa M, Ochiai A. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012; 103: 2012-2020 [PMID: 22931216 DOI: 10.1111/j.1349-7006.2012.02411.x]
13. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617 [PMID: 20427809 DOI: 10.1056/NEJMra0901557]
14. Hidalgo M. New insights into pancreatic cancer biology. Ann Oncol 2012; 23 Suppl 10: x135-x138 [PMID: 22987949 DOI: 10.1093/annonc/mds313]
15. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 [PMID: 9196156]
16. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, Sandvold ML. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 2009; 44: 782-786 [PMID: 19214867 DOI: 10.1080/00365520902745039]
17. Ansari D, Tingstedt B, Andersson R. Pancreatic cancer-cost for overtreatment with gemcitabine. Acta Oncol 2013; 52: 1146-1151 [PMID: 23244671 DOI: 10.3109/0284186X.2012.744 140]
18. Jarboe J, Saif MW. First line therapy for metastatic pancreatic cancer. JOP 2013; 14: 340-343 [PMID: 23846923 DOI: 10.6092/1590-8577/1667]
19. Ahmed A, Redmond HP, Wang JH. Links between Toll-like receptor 4 and breast cancer. Oncoimmunology 2013; 2: e22945 [PMID: 23526132 DOI: 10.4161/onci.22945]
20. Eyking A, Ey B, Rünzi M, Roig AI, Reis H, Schmid KW, Gerken G, Podolsky DK, Cario E. Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 2011; 141: 2154-2165 [PMID: 21920464 DOI: 10.1053/j.gastro.2011.08.043]
21. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012; 13: e301-e310 [PMID: 22748269 DOI: 10.1016/S1470-2045(12)70126-2]
22. Morse DL, Balagurunathan Y, Hostetter G, Trissal M, Tafreshi NK, Burke N, Lloyd M, Enkemann S, Coppola D, Hruby VJ, Gillies RJ, Han H. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol 2010; 80: 748-754 [PMID: 20510208 DOI: 10.1016/j.bcp.2010.05.018]
23. Rosenberg JS, Singh S, Raul S, Tong Z, Guha S. Pancreatic cancer screening by TLR phenotyping. Cancer Research 2011; 71: Abstract nr 894 [DOI: 10.1158/1538-7445.AM2011-894]
24. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; 2010: [PMID: 20706656 DOI: 10.1155/2010/672395]
25. Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 2011; 11: 702-712 [PMID: 21719349 DOI: 10.1016/S1473-3099(11)70099-8]
26. O'Neill LA, Bowie AG. The family of five: TIR-domaincontaining adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-364 [PMID: 17457343 DOI: 10.1038/ nri2079]
27. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-197 [PMID: 19474110 DOI: 10.1124/pr.109.001073]
28. Anders HJ, Banas B, Schlöndorff D. Signaling danger: tolllike receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15: 854-867 [PMID: 15034087 DOI: 10.1097/01.ASN.0000121781.89599.16]
29. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, Braun-Fahrländer C, Nowak D, Martinez FD. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 2004; 113: 482-488 [PMID: 15007351 DOI: 10.1016/j.jaci.2003.12.374]
30. Satoh M, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front Biosci 2008; 13: 6708-6715 [PMID: 18508689 DOI: 10.2741/3397]
31. Morr M, Takeuchi O, Akira S, Simon MM, Mühlradt PF. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol 2002; 32: 3337-3347 [PMID: 12432564]
32. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Mühlradt PF, Akira S. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol 2000; 164: 554-557 [PMID: 10623793]
33. Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Mühlradt PF, Schmidt J, Märten A. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004; 53: 355-361 [PMID: 14960515 DOI: 10.1136/ gut.2003.026005]
34. Weigt H, Mühlradt PF, Emmendörffer A, Krug N, Braun A. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 2003; 207: 223-233 [PMID: 12777064 DOI: 10.1078/0171-2985-00234]
35. Schmidt J, Welsch T, Jäger D, Mühlradt PF, Büchler MW, Märten A. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007; 97: 598-604 [PMID: 17667928 DOI: 10.1038/ sj.bjc.6603903]
36. Sun C, Rosendahl AH, Wang XD, Wu DQ, Andersson R. Polysaccharide-K (PSK) in cancer--old story, new possibilities? Curr Med Chem 2012; 19: 757-762 [PMID: 22204346 DOI: 10.2174/092986712798992020]
37. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S, Kawashima M, Niibe H. Effect of Krestin as adjuvant treatment following radical radiotherapy in nonsmall cell lung cancer patients. Cancer Detect Prev 1997; 21: 71-77 [PMID: 9043766]
38. Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, Dang Y, Martzen M, Standish LJ, Disis ML. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 2011; 17: 67-76 [PMID: 21068144 DOI: 10.1158/1078-0432.CCR-10-1763]
39. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004; 90: 1003-1010 [PMID: 14997197 DOI: 10.1038/sj.bjc.6601619]
40. Rosendahl AH, Sun C, Wu D, Andersson R. Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells. Pancreatology 2012; 12: 467-474 [PMID: 23217280 DOI: 10.1016/j.pan.2012.09.004]
41. Huynh AS, Chung WJ, Cho HI, Moberg VE, Celis E, Morse DL, Vagner J. Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. J Med Chem 2012; 55: 9751-9762 [PMID: 23098072 DOI: 10.1021/ jm301002f]
42. Huynh AS, Patek R, Abrahams D, Baldwin MK, Lioyd MC, Centeno BA, Vagner J, Gillies R, Morse DL. Intraoperative detection of pancreatic cancer using tumor targeted fluorescent probes. Mol Imaging Biol 2012; 14: S979
43. Kim SA, Lee Y, Jung DE, Park KH, Park JY, Gang J, Jeon SB, Park EC, Kim YG, Lee B, Liu Q, Zeng W, Yeramilli S, Lee S, Koh SS, Song SY. Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci 2009; 100: 828-836 [PMID: 19302292 DOI: 10.1111/j.1349-7006.2009.01106.x]
44. Lee Y, Kim SJ, Park HD, Park EH, Huang SM, Jeon SB, Kim JM, Lim DS, Koh SS. PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression. Oncogene 2010; 29: 56-67 [PMID: 19784070 DOI: 10.1038/onc.2009.298]
45. Park HD, Lee Y, Oh YK, Jung JG, Park YW, Myung K, Kim KH, Koh SS, Lim DS. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 2011; 30: 201-211 [PMID: 20802527 DOI: 10.1038/onc.2010.401]
46. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004; 22: 3302-3308 [PMID: 15310773 DOI: 10.1200/ JCO.2004.08.095]
47. Soga Y, Komori H, Miyazaki T, Arita N, Terada M, Kamada K, Tanaka Y, Fujino T, Hiasa Y, Matsuura B, Onji M, Nose M. Toll-like receptor 3 signaling induces chronic pancreatitis through the Fas/Fas ligand-mediated cytotoxicity. Tohoku J Exp Med 2009; 217: 175-184 [PMID: 19282652 DOI: 10.1620/ tjem.217.175]
48. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 2009; 69: 8710-8717 [PMID: 19887600 DOI: 10.1158/0008-5472.CAN-09-1602]
49. Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, Badar S, Hajdu CH, Frey AB, Bar-Sagi D, Miller G. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 2012; 209: 1671-1687 [PMID: 22908323 DOI: 10.1084/ jem.20111706]
50. Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, Slominski A, Wortsman J, Harii N, Kohn AD, Moon RT, Schwartz FL, Goetz DJ, Kohn LD, McCall KD. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res 2009; 15: 4114-4122 [PMID: 19470740 DOI: 10.1158/1078-0432. CCR-09-0005]
51. Katoh M, Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 2009; 23: 763-769 [PMID: 19424602 DOI: 10.3892/ijmm_00000190]
52. Harii N, Lewis CJ, Vasko V, McCall K, Benavides-Peralta U, Sun X, Ringel MD, Saji M, Giuliani C, Napolitano G, Goetz DJ, Kohn LD. Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis. Mol Endocrinol 2005; 19: 1231-1250 [PMID: 15661832 DOI: 10.1210/me.2004-0100]
53. Kleinridders A, Schenten D, Könner AC, Belgardt BF, Mauer J, Okamura T, Wunderlich FT, Medzhitov R, Brüning JC. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 2009; 10: 249-259 [PMID: 19808018 DOI: 10.1016/ j.cmet.2009.08.013]
54. Vaz J, Akbarshahi H, Andersson R. Controversial role of toll-like receptors in acute pancreatitis. World J Gastroenterol 2013; 19: 616-630 [PMID: 23431068 DOI: 10.3748/wjg.v19. i5.616]
55. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-127 [PMID: 17615359 DOI: 10.1126/science.1140488]
56. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208: 469-478 [PMID: 21339327 DOI: 10.1084/jem.20101876]
57. Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH. Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines. J Immunol 2013; 190: 1859-1872 [PMID: 23296709 DOI: 10.4049/jimmunol.1201725]
58. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H, Katano M. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 2009; 100: 725-731 [PMID: 19722233 DOI: 10.1002/jso.21392]
59. Bloomston M, Zervos EE, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002; 9: 668-674 [PMID: 12167581 DOI: 10.1007/BF02574483]
60. Del Pozo JL. Primers on molecular pathways: lipopolysaccharide signaling-potential role in pancreatitis and pancreatic cancer. Pancreatology 2010; 10: 114-118 [PMID: 20460943 DOI: 10.1159/000299987]
61. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, Ding JL. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 2013; 93: 844-854 [PMID: 23752129 DOI: 10.1038/labinvest. 2013.69]
62. Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010; 16: 2881-2888 [PMID: 20556833 DOI: 10.3748/wjg.v16.i23.2881]
63. Fan P, Zhang JJ, Wang B, Wu HQ, Zhou SX, Wang CY, Zhang JH, Tian Y, Wu HS. Hypoxia-inducible factor-1 upregulates the expression of Toll-like receptor 4 in pancreatic cancer cells under hypoxic conditions. Pancreatology 2012; 12: 170-178 [PMID: 22487528 DOI: 10.1016/j.pan.2012.02.015]
64. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559 [PMID: 17479101 DOI: 10.1038/nm1589]
65. Zambirinis CP, Miller G. Signaling via MYD88 in the pancreatic tumor microenvironment: A double-edged sword. Oncoimmunology 2013; 2: e22567 [PMID: 23483804 DOI: 10.4161/onci.22567]
66. Zambirinis CP, Ochi A, Barilla R, Greco S, Deutsch M, Miller G. Induction of TRIF-or MYD88-dependent pathways perturbs cell cycle regulation in pancreatic cancer. Cell Cycle 2013; 12: 1153-1154 [PMID: 23549168 DOI: 10.4161/cc.24488]
67. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, Greco S, Deutsch M, Medina-Zea MV, Bin Saeed U, Ego-Osuala MO, Hajdu C, Miller G. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 2012; 122: 4118-4129 [PMID: 23023703 DOI: 10.1172/JCI63606]
68. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745 [PMID: 11130078 DOI: 10.1038/35047123]
69. Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tinguely M, Hersberger M, Bernasconi M, Nadal D. TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis 2012; 3: e323 [PMID: 22717578 DOI: 10.1038/cddis.2012.60]
70. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484 [PMID: 16763660 DOI: 10.1038/nrd2059]
71. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011; 128: 897-907 [PMID: 20473889 DOI: 10.1002/ijc.25399]
72. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C, Menard S, Balsari A. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005; 65: 6388-6393 [PMID: 16024642 DOI: 10.1158/0008-5472.CAN-05-0602]
73. Friess H, Wang L, Zhu Z, Gerber R, Schröder M, Fukuda A, Zimmermann A, Korc M, Büchler MW. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg 1999; 230: 767-774; discussion 774-775 [PMID: 10615931 DOI: 10.1097/00000658-199912000-00005]
74. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012; 38: 843-853 [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004]
75. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a monoclo-nal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22: 2610-2616 [PMID: 15226328 DOI: 10.1200/JCO.2004.12.040]
76. Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006; 12: 577-583 [PMID: 16428503 DOI: 10.1158/1078-0432. CCR-05-1943]
77. Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res 2011; 17: 6531-6541 [PMID: 21890455 DOI: 10.1158/1078-0432.CCR-10-3376]
78. Liu K, Anderson GP, Bozinovski S. DNA vector augments inflammation in epithelial cells via EGFR-dependent regulation of TLR4 and TLR2. Am J Respir Cell Mol Biol 2008; 39: 305-311 [PMID: 18403779 DOI: 10.1165/rcmb.2007-0458OC]
79. Wu HQ, Wang B, Zhu SK, Tian Y, Zhang JH, Wu HS. Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer. World J Gastroenterol 2011; 17: 996-1003 [PMID: 21448350 DOI: 10.3748/wjg.v17.i8.996]
80. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 699-716 [PMID: 22934262 DOI: 10.4161/onci.20696]
81. Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 2013; 144: 1230-1240 [PMID: 23622132 DOI: 10.1053/j.gastro.2012.12.042]
82. Venook AP, Stagg RJ, Lewis BJ. Regional chemotherapy for colorectal cancer metastatic to the liver. Oncology (Williston Park) 1988; 2: 19-26 [PMID: 3079322 DOI: 10.1158/1078-0432. CCR-10-3074]
83. Ansari D, Urey C, Gundewar C, Bauden MP, Andersson R. Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases. Scand J Gastroenterol 2013; 48: 1183-1187 [PMID: 24047396 DOI: 10.3109/00365521. 2013.832368]
84. Hamzah J, Altin JG, Herringson T, Parish CR, Hämmerling GJ, O'Donoghue H, Ganss R. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol 2009; 183: 1091-1098 [PMID: 19561111 DOI: 10.4049/jimmunol.0900736]
85. Fresno M, Alvarez R, Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem 2011; 117: 151-164 [PMID: 21599616 DOI: 10.3109/13813455.2011.5 62514]